Jean Michel Molina
Overview
Explore the profile of Jean Michel Molina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
545
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liegeon G, Duffy A, Brooks C, Honour H, Pozniak A, Molina J
HIV Med
. 2023 Dec;
25(3):353-360.
PMID: 38040445
Objectives: We conducted a survey to evaluate HIV pre-exposure prophylaxis (PrEP) practices in a European clinical research network on HIV, hepatitis, and global infectious diseases (NEAT ID). Methods: An online...
2.
Salmona M, Lascoux-Combe C, Nere M, Rubenstein E, Molina J, Delaugerre C, et al.
J Antimicrob Chemother
. 2023 May;
78(7):1802-1803.
PMID: 37147875
No abstract available.
3.
Gras J, Nere M, Peraldi M, Bonnet-Madin L, Salmona M, Taupin J, et al.
Transpl Infect Dis
. 2023 Feb;
25(2):e14012.
PMID: 36748721
Background: Among kidney transplant recipients (KTR) with BK virus associated nephropathy (BKVN), BKV genotypes' evolution and anti-BKV humoral response are not well established. We aim to analyze BKV replication and...
4.
Gras J, Le Flecher A, Dupont A, Verine J, Amara A, Delaugerre C, et al.
BMC Infect Dis
. 2023 Feb;
23(1):74.
PMID: 36747162
Background: Following kidney transplantation, BK virus associated nephropathy (BKVN) occurs in 1 to 10% of kidney transplant recipients (KTR) and represents a major cause of graft loss. We aim at...
5.
Lions C, Laroche H, Mora M, Pialoux G, Cotte L, Cua E, et al.
HIV Med
. 2022 Aug;
24(2):191-201.
PMID: 35943165
Objectives: Our objective was to identify missed opportunities for the use of pre-exposure prophylaxis (PrEP) in people with recently acquired HIV, factors associated with PrEP knowledge, and reasons for not...
6.
Delaugerre C, Assoumou L, Maylin S, Minier M, Gabassi A, Genin M, et al.
Open Forum Infect Dis
. 2022 Jul;
9(7):ofac188.
PMID: 35791355
The potential preventive efficacy of tenofovir/emtricitabine on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was assessed in human immunodeficiency virus preexposure prophylaxis (PrEP) users. Prevalence of SARS-CoV-2 immunoglobulin G...
7.
Molina J, Ene L, Cahn P, Fatkenheuer G, Van Wijngaerden E, Lombaard J, et al.
Antivir Ther
. 2022 Apr;
26(6-8):95-105.
PMID: 35485339
Background: To evaluate the long-term safety and efficacy of rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), in combination with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) in human immunodeficiency virus (HIV)-infected...
8.
Ryom L, de Miguel R, Cotter A, Podlekareva D, Beguelin C, Waalewijn H, et al.
HIV Med
. 2022 Mar;
23(8):849-858.
PMID: 35338549
Background: The European AIDS Clinical Society (EACS) Guidelines were revised in 2021 for the 17th time with updates on all aspects of HIV care. Key Points Of The Guidelines Update:...
9.
Zeggagh J, Bauer R, Delaugerre C, Carette D, Fressard L, Charreau I, et al.
AIDS
. 2022 Feb;
36(8):1129-1134.
PMID: 35142708
Objective: High rates of sexually transmitted infections (STIs) have been reported among pre-exposure prophylaxis (PrEP) users. We wished to assess the incidence and risk factors for recurrent STIs. Design: The...
10.
Bettuzzi T, Jourdes A, Robineau O, Alcaraz I, Manda V, Molina J, et al.
Lancet Infect Dis
. 2021 May;
21(10):1441-1447.
PMID: 34051142
Background: Intravenous benzylpenicillin is the gold-standard treatment for neurosyphilis, but it requires prolonged hospitalisation. Ceftriaxone is a possible alternative treatment, the effectiveness of which remains unclear. We aimed to assess...